Desmopressin

Desmopressin (often called DDAVP) is a long-established prescription medicine that tells the kidneys to hold on to water, so the body makes less urine. It is a lab-made version of vasopressin, the body's own antidiuretic hormone. It is used for a condition where the body cannot concentrate urine at all (diabetes insipidus), for bedwetting in children, for adults who wake repeatedly at night to urinate, and in some bleeding disorders. It is FDA-approved and comes as tablets, melts, nasal sprays and an injection.

Desmopressin has been studied mostly in bedwetting and in night-time urination. In adults with an enlarged prostate, adding it to a standard prostate medicine cut night-time trips to the bathroom by about two thirds and roughly doubled the stretch of uninterrupted sleep. In children, though, one trial that compared it head to head with a bedwetting alarm found the alarm did better. The most important research is about its main risk: pooled trial data show it can drop blood sodium too low, more so with higher doses, older age and reduced kidney function — which is why the researchers proposed using the lowest effective dose and checking sodium before and during treatment. The honest part: this is a real risk that has shaped how the drug is prescribed, not a footnote.

FDA-approved prescription drug, long established. A synthetic analogue of vasopressin (antidiuretic hormone) used in central diabetes insipidus, bedwetting (nocturnal enuresis), night-time urination in adults (nocturia), and certain bleeding disorders. Approved indications and formulations are set by current labeling, verified against FDA labeling on accessdata.fda.gov and DailyMed, 2026-08-30. Boxed warning — hyponatremia. It applies to some formulations and not others. Carries it: the injection (DDAVP injection; Sun generic) — the currently-marketed product that carries it — plus two discontinued products, Nocdurna sublingual tablets and Noctiva nasal spray. Does not carry it: the marketed nasal sprays (0.01%) and the marketed oral tablets. The injection carries it; the marketed nasal sprays and oral tablets do not. WADA status. Desmopressin is explicitly named on the 2026 WADA Prohibited List, under S5 (Diuretics and Masking Agents), prohibited at all times — in and out of competition. All substances in the S5 class are Specified Substances. Verified verbatim against the 2026 list text, 2026-08-04. Most entries in this library are "not named but captured by S0 because they are unapproved." Desmopressin is the reverse: an approved medicine that is named outright. Anyone in regulated sport must treat this as a prohibited substance and speak to their anti-doping organization before use. Not DEA-scheduled (prescription, non-controlled).

Desmopressin is a prescription drug. Its main risk is low blood sodium (hyponatraemia), and pooled trial data identify dose, older age, lower baseline sodium and reduced kidney function as the drivers — which is why researchers proposed the lowest effective dose plus sodium checks before starting and during treatment. Some desmopressin products carry an FDA boxed warning for that same risk — the most serious warning label US regulators issue — and which ones depends on the formulation. The injection carries it, and so did two products no longer sold (Nocdurna sublingual tablets and Noctiva nasal spray). The nasal sprays and oral tablets sold today do not. The warning says severe hyponatraemia can be life-threatening, leading to seizures, coma, respiratory arrest or death. It is contraindicated in people at increased risk — those drinking excessive fluids, those with an illness causing fluid or electrolyte imbalance, and those taking loop diuretics or systemic or inhaled glucocorticoids. It calls for normal blood sodium before starting or restarting, a check within 7 days and at about one month, then periodically, with more frequent checks from age 65. In sport, this one is different from most of this library: desmopressin is explicitly named on the WADA Prohibited List under S5 (Diuretics and Masking Agents) and is prohibited at all times, in and out of competition. Anyone in regulated sport should treat it as prohibited and consult their anti-doping organization. VialWise is a research and educational reference, not medical advice — consult a licensed professional.

⚠️ This is an approved prescription medicine, not a research peptide. Desmopressin is dispensed by a pharmacy and used under clinical supervision. The reconstitution and self-dosing workflows used elsewhere in this library do not apply. Information here is informational, not medical advice.

⚠️ The main safety story is hyponatraemia, and it is not a footnote. Desmopressin's whole mechanism is water retention, so the predictable failure mode is dilutional low blood sodium. Pooled trial data identified dose, age, baseline sodium and kidney function as risk factors, and the researchers responded by proposing a lower, sex-specific dose plus a sodium-monitoring schedule.[¹] Take that as the central fact about this drug rather than a listed side effect.

Desmopressin, also written DDAVP (1-deamino-8-D-arginine vasopressin), is a synthetic analogue of vasopressin — the hormone that tells the kidney to reabsorb water. It has been in clinical use for decades and has been marketed under several names including Minirin, Nocdurna and Noctiva — but Nocdurna and Noctiva are both discontinued (see the formulations table below). In the US the products currently listed as marketed in FDA's Drugs@FDA are DDAVP and generic desmopressin acetate; neither Nocdurna nor Noctiva appears there at all.

Mechanism. Vasopressin acts on renal receptors to concentrate urine and conserve water. Desmopressin is modified to retain that antidiuretic action with a longer duration while largely dropping vasopressin's blood-pressure effects. Clinically this means less urine produced over the dosing window — useful when the problem is either too little natural vasopressin (central diabetes insipidus) or too much urine made overnight (nocturnal polyuria, the mechanism behind much nocturia and bedwetting).[¹][³]

Evidence quality. The evidence base is unusual for this library: the drug is old, so there is no single modern pivotal trial to point to. Instead there are many trials across several indications, plus pooled safety analyses. This entry uses three:

- A pooled analysis of three clinical trials in nocturia examined who develops clinically significant hyponatraemia.[¹] Dose, age, baseline serum sodium and kidney function (eGFR) were significant risk factors in both sexes — the same risk factors that predict hyponatraemia in the general population.[¹] The authors proposed sex-specific minimum effective dosing, lower in women than in men, using the orally disintegrating form plus a monitoring scheme: baseline sodium must be ≥135 mmol/L, with additional checks at week 1 and month 1 for patients at elevated risk because they are aged ≥65 or taking other medications associated with hyponatraemia.[¹] Applying that scheme retrospectively, all patients with clinically significant hyponatraemia would have been screened out, leaving only mild, non-clinically-significant cases.[¹] ⚠️ The authors are employees of Ferring Pharmaceuticals, which markets desmopressin.[¹] - A randomized comparison in children with monosymptomatic nocturnal enuresis, 93 patients, assigned to alarm, desmopressin, imipramine, or behavioral therapy alone.[²] Counting full plus partial responders: alarm 100%, imipramine 73.7%, desmopressin 63.6%.[²] The authors' conclusion is explicit — alarms were the most effective treatment, superior to both drugs.[²] ⚠️ Small study, and the authors themselves list the sample size and the absence of an end-of-study voiding diary as weaknesses.[²] - A randomized trial in 248 men with benign prostatic hyperplasia and nocturia compared tamsulosin alone against tamsulosin plus low-dose desmopressin melt.[³] Night voids fell 64.3% with the combination versus 44.6% with tamsulosin alone, and the first uninterrupted sleep period rose from 82.1 to 160.0 minutes on the combination versus 83.2 to 123.8 minutes on tamsulosin alone (p < 0.001).[³] No serious adverse effects were reported in either group over 3 months.[³]

Regulatory status (US). FDA-approved, long established, across multiple formulations and indications. Indications by formulation are set by current labeling — verified against FDA labeling on accessdata.fda.gov and DailyMed, 2026-08-30. Not DEA-scheduled.

Boxed warning — hyponatremia. This is formulation-specific, not molecule-wide. The FDA's most serious warning applies to some desmopressin products and not others. The injection carries it, as did the two discontinued products; the marketed nasal sprays and oral tablets do not.

What the warning says. Severe hyponatremia can be life-threatening, leading to seizures, coma, respiratory arrest or death. It is contraindicated in patients at increased risk: excessive fluid intake; illnesses causing fluid or electrolyte imbalance; and concomitant loop diuretics or systemic or inhaled glucocorticoids. It requires normal serum sodium before starting or resuming, then measurement within 7 days and at approximately one month, then periodically — with more frequent monitoring in patients aged 65 and over.

This is the same hyponatraemia risk the pooled trial analysis below characterises;[¹] the boxed warning is the regulatory expression of it on the formulations that carry it, and the trial-derived monitoring scheme sits alongside it rather than replacing it.

Regulatory status (sport — WADA). Desmopressin is explicitly named on the 2026 WADA Prohibited List (checked directly against the list text, 2026-08-04). It appears under S5 — Diuretics and Masking Agents, which is prohibited at all times (in- and out-of-competition), and the section states that all prohibited substances in that class are Specified Substances. In the list, desmopressin is itemised in the same block as intravenous plasma expanders (albumin, dextran, hydroxyethyl starch, mannitol) and probenecid.

Note also the practical consequence built into that same section: the list specifies that detecting certain threshold-limited substances in conjunction with a diuretic or masking agent is treated differently. Anyone in regulated sport should treat desmopressin as prohibited and consult their National Anti-Doping Organization about therapeutic use exemptions before any use.

Commonly reported

• Pooled trial data identified dose, age, baseline serum sodium and kidney function as significant risk factors in both sexes.[¹]
• Additional sex-specific predictors were found: in men, arthritis and use of drugs for bone disease; in women, raised monocytes and absence of lipid-modifying drugs.[¹]
• With a minimum effective dose plus the proposed monitoring scheme, retrospective application showed only mild, non-clinically-significant hyponatraemia would have remained — within the range seen with other drugs associated with hyponatraemia.[¹]
• Severity range matters: mild low sodium may be asymptomatic, but clinically significant hyponatraemia is the reason this monitoring exists.
• In the pediatric enuresis trial, no patients in either drug group developed cutaneous drug reactions or central nervous system symptoms.[²]
• In the BPH nocturia trial, no serious adverse effects were reported in either group over 3 months.[³]

Boxed warning (formulation-specific) — hyponatremia. The injection carries the FDA's most serious warning label; the discontinued Nocdurna and Noctiva products did too. The marketed nasal sprays (0.01%) and oral tablets do not. Severe hyponatremia can be life-threatening — seizures, coma, respiratory arrest or death. Contraindicated with excessive fluid intake, with illnesses causing fluid or electrolyte imbalance, and with concomitant loop diuretics or systemic/inhaled glucocorticoids. Requires normal serum sodium before starting or resuming, a check within 7 days and at ~1 month, then periodically; more frequent monitoring at age 65+.

This is a prescription medicine. Use outside a prescribed, clinically supervised context is outside everything the evidence base covers — and for a drug whose main risk is a dangerous electrolyte shift, the monitoring is not optional.

Baseline serum sodium below 135 mmol/L — the pooled analysis proposes this as a threshold that should exclude a patient from starting.[¹]

Age ≥65 — an identified risk factor and a trigger for added sodium monitoring at week 1 and month 1.[¹]

Reduced kidney function (lower eGFR) — an identified hyponatraemia risk factor.[¹]

Concomitant medications associated with hyponatraemia — a trigger for added monitoring.[¹]

Pregnancy and lactation — not addressed by the sources here. Refer to current labeling.

Pediatric use — desmopressin is used in children for enuresis;[²] dosing and suitability are clinical decisions.

Regulatory note (sport): Explicitly named on the 2026 WADA Prohibited List, S5 (Diuretics and Masking Agents), prohibited at all times, in and out of competition. A Specified Substance — which affects how a case is judged, not whether it is allowed. Consult your anti-doping organization.

Not DEA-scheduled.

Peptide

A short chain of amino acids, the building blocks of proteins. Many compounds in this library are peptides.

Vasopressin (ADH)

Antidiuretic hormone — the body's signal to the kidneys to retain water. Desmopressin is a longer-lasting synthetic version.

Hyponatraemia

Blood sodium that is too low. Mild cases may cause no symptoms; severe cases can cause confusion, seizures and can be dangerous. It is desmopressin's principal risk.

Nocturia

Waking one or more times during the night specifically to urinate.

Specified Substance (WADA)

A category on the anti-doping list for substances more likely to be taken for genuine medical reasons. It can affect how a case is judged — it does not mean the substance is permitted.

1. Juul KV, Malmberg A, van der Meulen E, Walle JV, Nørgaard JP. (2017). Low-dose desmopressin combined with serum sodium monitoring can prevent clinically significant hyponatraemia in patients treated for nocturia. BJU International, 119(5):776–784.(PMID 27862898)
2. Mello MF, Locali RF, Araujo RM, Reis JN, Saiovici S, Mello LF, Trigo Rocha FE. (2023). A prospective and randomized study comparing the use of alarms, desmopressin and imipramine in the treatment of monosymptomatic nocturnal enuresis. Journal of Pediatric Urology, 19(3):241–246.(PMID 36717289)
3. Ahmed AF, Maarouf A, Shalaby E, Gabr AH, Shahin A, Ghobish A. (2015). The impact of adding low-dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia. World Journal of Urology, 33(5):649–657.(PMID 25138579)

• CagriSema — both carry a boxed warning
• Dulaglutide — both carry a boxed warning
• Exenatide — both carry a boxed warning
• Liraglutide — both carry a boxed warning
• Orforglipron — both carry a boxed warning
• Pramlintide — both carry a boxed warning